DPP-4 Inhibitors in Combination with Insulin Therapy for Type 2 Diabetes Patients

Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and reducing glucagon release.

Read more

Posted in Type II Drugs